(umeclidinium/vilanterol inhalation powder)
(meningococcal groupB vaccine (rDNA, component, adsorbed))
(benzoyl peroxide/clindamycin phosphate)
(salmeterol xinafoate/fluticasone propionate)
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the GSK group of companies.